VIR
Vir Biotechnology, Inc.6.48
-0.24-3.57%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
901.53MP/E (TTM)
-Basic EPS (TTM)
-3.62Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Vir Biotechnology's Q2 revenue dipped to $1.2M from $3.1M y/y, driven by lower collaboration inflows, while YTD revenue fell sharply to $4.2M from $59.5M amid prior-year milestones. Operating loss narrowed to $118.4M from $158.6M y/y, thanks to reduced R&D spend on clinical costs and personnel, yet net loss widened to $111.0M from $138.4M due to a $3.4M fair-value drop in equity investments. Diluted EPS improved to $(0.80) from $(1.02), aligning with 138.4M weighted shares and no anti-dilution effects. Cash and equivalents stood at $211.1M with $892.1M total liquidity, offset by $95.2M restricted for milestones; free cash flow not disclosed in the 10-Q. The September 2024 Amunix license closed for $100.0M cash plus $75.0M escrowed milestone, recognizing $102.8M IPR&D expensed immediately. Pipeline advances, including first dosing in VIR-5525's phase 1 trial. Competition in oncology targets remains fierce.
8-K
Pipeline advances, solid cash
Vir Biotechnology kicked off its ECLIPSE registrational program for chronic hepatitis delta, enrolling first patients in ECLIPSE 2 and 3 to test tobevibart-elebsiran combo against bulevirtide. It dosed the first patient in Phase 1 for VIR-5525, an EGFR-targeting PRO-XTEN™ T-cell engager, bolstering its oncology push with three ongoing trials. Cash stands at $892.1 million, funding ops into mid-2027, while Q2 net loss narrowed to $111.0 million from $138.4 million. Restructuring cuts trimmed R&D and SG&A expenses.
8-K
First VIR-5525 patient dosed
Vir Biotechnology dosed the first patient in its Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR for solid tumors like NSCLC and CRC. The open-label study assesses safety, pharmacokinetics, and efficacy alone or with pembrolizumab, leveraging PRO-XTEN™ technology to activate selectively in tumors and curb toxicity. This triggers a $75 million milestone payment to Sanofi, recorded as R&D expense in Q3 2025. Dose escalations for sister candidates VIR-5818 and VIR-5500 show early promise. Early data may falter.
8-K
Annual meeting results
Vir Biotechnology's stockholders, at the May 29, 2025 annual meeting, elected Jeffrey S. Hatfield and Saira Ramasastry as Class III directors through 2028, with Hatfield drawing 10.9 million withheld votes amid strong overall support. They also approved executive compensation on an advisory basis, with 100.5 million votes in favor, and ratified Ernst & Young as auditors for 2025, passing overwhelmingly at 116.3 million for. Board continuity holds firm.
ASMB
Assembly Biosciences, Inc.
33.50-1.10
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
MRNA
Moderna, Inc.
29.89-0.03
NNVC
NanoViricides, Inc.
1.29+0.06
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VRAX
Virax Biolabs Group Limited
0.40-0.01
VRDN
Viridian Therapeutics, Inc.
32.85-0.18
VXRT
Vaxart, Inc.
0.37+0.01